These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Identification of drug modifiers for RYR1-related myopathy using a multi-species discovery pipeline. Volpatti JR; Endo Y; Knox J; Groom L; Brennan S; Noche R; Zuercher WJ; Roy P; Dirksen RT; Dowling JJ Elife; 2020 Mar; 9():. PubMed ID: 32223895 [TBL] [Abstract][Full Text] [Related]
6. Oxidative stress and successful antioxidant treatment in models of RYR1-related myopathy. Dowling JJ; Arbogast S; Hur J; Nelson DD; McEvoy A; Waugh T; Marty I; Lunardi J; Brooks SV; Kuwada JY; Ferreiro A Brain; 2012 Apr; 135(Pt 4):1115-27. PubMed ID: 22418739 [TBL] [Abstract][Full Text] [Related]
7. Mouse model of severe recessive RYR1-related myopathy. Brennan S; Garcia-Castañeda M; Michelucci A; Sabha N; Malik S; Groom L; Wei LaPierre L; Dowling JJ; Dirksen RT Hum Mol Genet; 2019 Sep; 28(18):3024-3036. PubMed ID: 31107960 [TBL] [Abstract][Full Text] [Related]
8. Ryanodine receptor type 1 content decrease-induced endoplasmic reticulum stress is a hallmark of myopathies. Vidal J; Fernandez EA; Wohlwend M; Laurila PP; Lopez-Mejia A; Ochala J; Lobrinus AJ; Kayser B; Lopez-Mejia IC; Place N; Zanou N J Cachexia Sarcopenia Muscle; 2023 Dec; 14(6):2882-2897. PubMed ID: 37964752 [TBL] [Abstract][Full Text] [Related]
9. Preclinical model systems of ryanodine receptor 1-related myopathies and malignant hyperthermia: a comprehensive scoping review of works published 1990-2019. Lawal TA; Wires ES; Terry NL; Dowling JJ; Todd JJ Orphanet J Rare Dis; 2020 May; 15(1):113. PubMed ID: 32381029 [TBL] [Abstract][Full Text] [Related]
10. Drug development for the treatment of RyR1-related skeletal muscle diseases. Murayama T; Kurebayashi N; Ishida R; Kagechika H Curr Opin Pharmacol; 2023 Apr; 69():102356. PubMed ID: 36842386 [TBL] [Abstract][Full Text] [Related]
11. 6-minute walk test as a measure of disease progression and fatigability in a cohort of individuals with RYR1-related myopathies. Witherspoon JW; Vasavada RP; Waite MR; Shelton M; Chrismer IC; Wakim PG; Jain MS; Bönnemann CG; Meilleur KG Orphanet J Rare Dis; 2018 Jul; 13(1):105. PubMed ID: 29970108 [TBL] [Abstract][Full Text] [Related]
12. RyR1-related myopathy mutations in ATP and calcium binding sites impair channel regulation. Yuan Q; Dridi H; Clarke OB; Reiken S; Melville Z; Wronska A; Kushnir A; Zalk R; Sittenfeld L; Marks AR Acta Neuropathol Commun; 2021 Nov; 9(1):186. PubMed ID: 34809703 [TBL] [Abstract][Full Text] [Related]
13. Identification of ER/SR resident proteins as biomarkers for ER/SR calcium depletion in skeletal muscle cells. Greer LK; Meilleur KG; Harvey BK; Wires ES Orphanet J Rare Dis; 2022 Jun; 17(1):225. PubMed ID: 35698232 [TBL] [Abstract][Full Text] [Related]
14. Understanding Symptoms in RYR1-Related Myopathies: A Mixed-Methods Analysis Based on Participants' Experience. Capella-Peris C; Cosgrove MM; Chrismer IC; Razaqyar MS; Elliott JS; Kuo A; Emile-Backer M; Meilleur KG Patient; 2020 Aug; 13(4):423-434. PubMed ID: 32329019 [TBL] [Abstract][Full Text] [Related]
15. Therapies for RYR1-Related Myopathies: Where We Stand and the Perspectives. Beaufils M; Travard L; Rendu J; Marty I Curr Pharm Des; 2022; 28(1):15-25. PubMed ID: 34514983 [TBL] [Abstract][Full Text] [Related]